Genmab

Oncology

Genmab

Danish drugmaker Genmab (OMX: GEN) is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

Danish drugmaker Genmab (OMX: GEN) is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

Founded in 1999, the company’s first marketed antibody, Arzerra (ofatumumab), entered the market after less than eight years in development.

It was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab. Ofatumumab is marketed under a co-development and collaboration agreement with GlaxoSmithKline and has been launched in 26 countries, as of December 2012.

It is continuing in development for other indications. In addition to ofatumumab, Genmab is building a deep pipeline of clinical and pre-clinical antibody products to treat cancer and for other diseases where there is an unmet medical need.

Genmab'’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Genmab is developing a pipeline of fully human antibody therapeutics for the treatment of cancer, with three products in clinical development and nine active pre-clinical product candidates. Its products are being studied in over 70 active clinical studies. Other products include Daratumumab, a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM).

Genmab also has 13 active pre-clinical pipeline product candidates including naked antibodies, bispecific antibodies developed using DuoBody technology, and Antibody-Drug Conjugates (ADC).


Latest Articles

Who's Who

Back to top